Articles Archives - Page 275 of 733

WednesdayJun 01, 2022 9:45 am

Kronos Advanced Technologies Inc. (KNOS) Committed to Providing Best Protection, Best Technology Amid Lingering Pandemic

WHO director-general warns COVID-19 is “most certainly not over” KNOS building reputation for effective, advanced, state-of-the-art air filtration and purification systems Company also offers Kronos(R)-designed graphene N95 face masks made in U.S. at NIOSH-certified facility While mask mandates have been lifted and life appears to be returning to normal in many places around the world, the COVID-19 pandemic is “most certainly not over,” reported Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (https://ibn.fm/8YfkT). The need for continued vigilance has spurred many companies, including Kronos Advanced Technologies (OTC: KNOS), that are working to provide people with protection against the deadly…

WednesdayJun 01, 2022 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients

A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM) Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”) Lexaria is consistently enhancing the delivery of APIs that affect current oral formulations: speed of onset, limited absorption, and low membrane permeability Lexaria has conducted numerous ground-breaking studies, some of which open up the possibility of fast-acting oral products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking Oral formulations account for approximately 90% of the global share of…

TuesdayMay 31, 2022 3:00 pm

DGE’s 2nd KOL Engagement Forum Designed To Foster Partnership Ties With KOLs

Life science companies and professionals are invited to attend Dynamic Global Events’ (“DGE”) 2nd KOL Engagement Forum, livestreaming June 1-2, 2022. A pioneer in organizing networking events, Dynamic Global Events focuses on delivering high-quality data and networking avenues to the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The forum is designed for medical and life science professionals to create strong networking ties and cultivate strong long-term relationships with the most influential thought leaders in the industry. In these uncertain times when there is growing distrust for institutions, these respected partnerships will foster confidence and lend credibility to the products. KOLs…

TuesdayMay 31, 2022 12:00 pm

CWCBExpo, the Premier B2B Cannabis, and Hemp Expo and Conference to Foster Lively Discussion on Industry Opportunities and Challenges Among Seasoned Professionals and Newcomers Alike

The Cannabis World Congress & Business Exposition (CWCBExpo) will be held between June 2-4, 2022, at the Javits Convention Center, Hall 3A, in New York City. Industry heavyweights, the foremost innovators, and pioneering thought leaders will take the stage to discuss emerging trends in cannabis, hemp, and allied sectors. The expo will provide a high-quality business-focused attendee base located in the premier East Coast US cannabis and hemp market. The three-day event will feature an Inside the Industry: Thought Leadership Series in an interactive “Talk Show” format. Co-hosts will include Carl Cameron, veteran journalist and former FOX News reporter; Faye…

TuesdayMay 31, 2022 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long,…

TuesdayMay 31, 2022 10:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Working to Alleviate Consumer Anxiety by Offering EVs with 600-Plus Mile Range

J.D. Power survey reports range was factor most cited in deciding what EV to buy Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022…

TuesdayMay 31, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical…

TuesdayMay 31, 2022 9:00 am

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking…

FridayMay 27, 2022 12:00 pm

Crypto Enthusiasts to Gather in Austin, TX for Four-Day 2022 Consensus Festival, Featuring Everything from Blockchain to Web3

Hosted by CoinDesk, the 2022 Consensus festival is slated for June 9-12, 2022, in Austin, Texas The festival features 15,000+ attendees, 400+ speakers, and 250+ event sponsors, catering to all sides of blockchain, crypto, Web3, NFTs and the Metaverse Web3 is the future of the internet – creating a decentralized technology that removes the control from the big tech companies and places it back in the hands of the users Venture Capitalist firm Andreessen Horowitz announced a $4.5 billion fund aimed at Web3; with one third of the funds dedicated exclusively to seed deals Coinbase has become the first crypto-based…

Site Search

Company Search

Category: Articles